Retatrutide Phase 3 Results: Weight Loss, Knee Pain, and Sleep Apnea
TRIUMPH-1 tested retatrutide for 80 weeks. Explore its weight-loss, knee-pain and sleep-apnea results, study limitations, and investigational status.
Read article
Clinical Trials
Coverage of peptide therapeutics tested in people: trial phases, endpoints, populations and topline results. These articles separate what a trial was designed to measure from what was reported, note sample sizes and comparators, and flag when results come from company announcements rather than peer-reviewed publications.
5 articles by Brian Gossett. Read our editorial standards.
Redasemtide: What Two Trials Reveal About Regenerative Peptide Research
Redasemtide showed an ulcer-closure signal in four patients, while a stroke trial missed its primary endpoint. Understand the regenerative peptide findings.
Read article
Peptide Clinical Trial Watch 2026: Beyond Weight Loss
A 2026 framework for tracking peptide clinical trials beyond weight loss — oncology PDCs, oral PCSK9, antimicrobial peptides, neurology and rare disease.
Read article
Promising Peptides in Clinical Trials 2026: Retatrutide, Cagrilintide & More
A long-form look at the most promising peptides currently in clinical trials — retatrutide, cagrilintide, survodutide, mazdutide and more — what stage each is at, and what the data shows so far.
Read article
PNC-27: The Cancer-Killing Peptide With Near-Perfect Early Results — And No Phase 3 Trial
PNC-27 selectively kills cancer cells across seven cancer types with no harm to normal cells in every study conducted. A deep look at the research, why it has never advanced to Phase 3 trials, and the uncomfortable economics of cancer drug development.
Read article